Is NANO MRNALtd (TSE:4571) A Risky Investment?
Jul 18
Japanese (NIKKEI) Biotech Industry Analysis
UpdatedAug 01, 2024
DataAggregated Company Financials
Companies32
- 7D1.9%
- 3M29.6%
- 1Y10.5%
- YTD23.9%
Over the last 7 days, the Biotech industry has dropped 3.1%, driven by a pullback from PeptiDream of 6.3%. In contrast, Chordia Therapeutics has gained 44%. Over the past 12 months, the industry was up 7.3%. As for the next few years, earnings are expected to grow by 19% per annum.
Industry Valuation and Performance
Has the Japanese Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Fri, 02 Aug 2024 | JP¥1.1t | JP¥187.5b | -JP¥16,095,901,000.00 | 57.1x | -66.6x | 5.7x |
| Sun, 30 Jun 2024 | JP¥994.5b | JP¥187.7b | -JP¥15,773,284,000.00 | 89.8x | -63x | 5.3x |
| Tue, 28 May 2024 | JP¥786.6b | JP¥195.7b | -JP¥14,072,545,000.00 | 94.1x | -55.9x | 4x |
| Thu, 25 Apr 2024 | JP¥753.5b | JP¥198.9b | -JP¥14,917,877,000.00 | 42.1x | -50.5x | 3.8x |
| Sat, 23 Mar 2024 | JP¥773.8b | JP¥194.2b | -JP¥15,457,633,000.00 | 60.7x | -50.1x | 4x |
| Mon, 19 Feb 2024 | JP¥811.8b | JP¥196.2b | -JP¥18,777,853,000.00 | 64.3x | -43.2x | 4.1x |
| Wed, 17 Jan 2024 | JP¥807.6b | JP¥222.3b | -JP¥12,605,455,000.00 | 17.5x | -64.1x | 3.6x |
| Fri, 15 Dec 2023 | JP¥747.8b | JP¥221.9b | -JP¥12,426,487,000.00 | 16.8x | -60.2x | 3.4x |
| Sun, 12 Nov 2023 | JP¥735.1b | JP¥221.1b | -JP¥8,758,085,000.00 | 17.1x | -83.9x | 3.3x |
| Tue, 10 Oct 2023 | JP¥812.4b | JP¥223.0b | -JP¥14,518,735,000.00 | 24.2x | -56x | 3.6x |
| Thu, 07 Sep 2023 | JP¥917.3b | JP¥225.4b | -JP¥19,581,085,000.00 | 46.8x | -46.8x | 4.1x |
| Sat, 05 Aug 2023 | JP¥894.4b | JP¥223.9b | -JP¥20,554,624,000.00 | 49.8x | -43.5x | 4x |
| Mon, 03 Jul 2023 | JP¥980.5b | JP¥223.0b | -JP¥19,224,671,000.00 | 61.2x | -51x | 4.4x |
| Wed, 31 May 2023 | JP¥926.3b | JP¥218.4b | -JP¥25,404,669,000.00 | 34x | -36.5x | 4.2x |
| Fri, 28 Apr 2023 | JP¥899.4b | JP¥218.1b | -JP¥20,115,522,000.00 | 20.7x | -44.7x | 4.1x |
| Sun, 26 Mar 2023 | JP¥930.7b | JP¥218.3b | -JP¥21,583,164,000.00 | 20.6x | -43.1x | 4.3x |
| Tue, 21 Feb 2023 | JP¥955.9b | JP¥216.2b | -JP¥18,991,580,000.00 | 21.4x | -50.3x | 4.4x |
| Thu, 19 Jan 2023 | JP¥906.0b | JP¥186.8b | -JP¥24,722,604,000.00 | 38.7x | -36.6x | 4.8x |
| Sat, 17 Dec 2022 | JP¥906.0b | JP¥186.8b | -JP¥24,723,433,000.00 | 43.6x | -36.6x | 4.8x |
| Mon, 14 Nov 2022 | JP¥884.6b | JP¥180.2b | -JP¥24,569,725,000.00 | 48.9x | -36x | 4.9x |
| Wed, 12 Oct 2022 | JP¥879.0b | JP¥176.5b | -JP¥24,974,270,000.00 | 42.4x | -35.2x | 5x |
| Fri, 09 Sep 2022 | JP¥908.6b | JP¥177.6b | -JP¥23,522,270,000.00 | 49.7x | -38.6x | 5.1x |
| Sun, 07 Aug 2022 | JP¥971.4b | JP¥170.1b | -JP¥18,370,562,000.00 | 20.7x | -52.9x | 5.7x |
| Tue, 05 Jul 2022 | JP¥861.6b | JP¥171.3b | -JP¥16,112,943,000.00 | 20x | -53.5x | 5x |
| Thu, 02 Jun 2022 | JP¥892.0b | JP¥169.3b | -JP¥13,461,721,000.00 | 11.2x | -66.3x | 5.3x |
| Sat, 30 Apr 2022 | JP¥1.0t | JP¥163.9b | -JP¥13,144,295,000.00 | 13.9x | -76.6x | 6.1x |
| Mon, 28 Mar 2022 | JP¥1.1t | JP¥164.2b | -JP¥13,044,654,000.00 | 15.4x | -84.1x | 6.7x |
| Wed, 23 Feb 2022 | JP¥1.1t | JP¥159.9b | -JP¥9,023,798,000.00 | n/a | -118.5x | 6.7x |
| Fri, 21 Jan 2022 | JP¥1.1t | JP¥163.5b | -JP¥5,447,358,000.00 | 16.6x | -204.6x | 6.8x |
| Sun, 19 Dec 2021 | JP¥1.2t | JP¥163.5b | -JP¥5,447,358,000.00 | 18.5x | -226.1x | 7.5x |
| Tue, 16 Nov 2021 | JP¥1.4t | JP¥158.0b | -JP¥10,586,746,000.00 | 19.7x | -128.4x | 8.6x |
| Thu, 14 Oct 2021 | JP¥1.4t | JP¥147.6b | -JP¥12,269,440,000.00 | 23x | -113.3x | 9.4x |
| Sat, 11 Sep 2021 | JP¥1.7t | JP¥147.9b | -JP¥14,140,440,000.00 | 25.5x | -119.7x | 11.4x |
| Mon, 09 Aug 2021 | JP¥1.6t | JP¥148.3b | -JP¥14,096,440,000.00 | 23.4x | -111.4x | 10.6x |
Price to Earnings Ratio
-111.4x
Current Industry PE
- Investors are relatively neutral on the Japanese Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.
- The industry is trading close to its 3-year average PS ratio of 5.4x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have deteriorated over the last three years.
- Meanwhile revenues for these companies have grown 8.2% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.
Industry Trends
Which industries have driven the changes within the Japanese Healthcare industry?
| JP Market | 0.12% | |
| Healthcare | 2.17% | |
| Biotech | 1.94% | |
| Biotech | 1.94% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 4592 SanBio | JP¥1.12k | 25.3% +JP¥15.4b | 96.8% | PB31.9x | |
| 4587 PeptiDream | JP¥2.69k | 2.0% +JP¥6.7b | 50.7% | PE142.8x | |
| 4564 OncoTherapy Science | JP¥60.00 | 39.5% +JP¥4.5b | 93.5% | PS25.9x | |
| 2160 GNI Group | JP¥2.29k | 3.9% +JP¥4.4b | 72.1% | PE12x | |
| 4563 AnGes | JP¥71.00 | 31.5% +JP¥4.0b | -27.6% | PS67.7x |
